| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7977488 | PHATHOM | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors |
Aug, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9186411 | PHATHOM | Pharmaceutical composition |
Aug, 2030
(6 years from now) | |
Voquezna is owned by Phathom.
Voquezna contains Vonoprazan Fumarate.
Voquezna has a total of 2 drug patents out of which 0 drug patents have expired.
Voquezna was authorised for market use on 01 November, 2023.
Voquezna is available in tablet;oral dosage forms.
Drug patent challenges can be filed against Voquezna from 03 May, 2026.
The generics of Voquezna are possible to be released after 11 August, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 01, 2026 |
| New Chemical Entity Exclusivity(NCE) | May 03, 2027 |
Drugs and Companies using VONOPRAZAN FUMARATE ingredient
NCE-1 date: 03 May, 2026
Market Authorisation Date: 01 November, 2023
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
VOQUEZNA family patents
